Capital International Investors Boosts Stake in BeOne Medicines Ltd. – Sponsored ADR $ONC

Capital International Investors boosted its holdings in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 3.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,046,058 shares of the company’s stock after acquiring an additional 161,052 shares during the quarter. Capital International Investors owned about 4.60% of BeOne Medicines worth $1,716,883,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Primecap Management Co. CA purchased a new position in shares of BeOne Medicines in the 2nd quarter valued at about $1,231,720,000. Temasek Holdings Private Ltd purchased a new stake in BeOne Medicines during the second quarter worth about $244,603,000. Marshall Wace LLP purchased a new stake in BeOne Medicines during the second quarter worth about $113,190,000. Baird Financial Group Inc. acquired a new position in BeOne Medicines during the second quarter worth about $82,895,000. Finally, Candriam S.C.A. purchased a new position in BeOne Medicines in the second quarter valued at about $67,852,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeOne Medicines Price Performance

NASDAQ:ONC opened at $302.29 on Tuesday. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $196.45 and a 12-month high of $385.22. The firm has a market cap of $33.15 billion, a price-to-earnings ratio of 119.96 and a beta of 0.53. The company’s 50-day moving average is $335.51 and its two-hundred day moving average is $330.31. The company has a current ratio of 3.41, a quick ratio of 3.08 and a debt-to-equity ratio of 0.22.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($1.02). The firm had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. BeOne Medicines had a return on equity of 10.70% and a net margin of 5.37%. Research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 EPS for the current year.

Insider Activity at BeOne Medicines

In other BeOne Medicines news, SVP Chan Henry Lee sold 1,660 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $349.52, for a total transaction of $580,203.20. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO John Oyler sold 24,369 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $302.87, for a total value of $7,380,639.03. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 102,656 shares of company stock valued at $31,567,496 over the last ninety days. 6.62% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have recently commented on ONC. Wall Street Zen lowered BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Barclays boosted their target price on BeOne Medicines from $394.00 to $405.00 and gave the stock an “overweight” rating in a research report on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Wednesday, January 21st. Jefferies Financial Group reaffirmed a “buy” rating and set a $420.00 price target on shares of BeOne Medicines in a research note on Monday, November 17th. Finally, Guggenheim boosted their price objective on shares of BeOne Medicines from $400.00 to $410.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $401.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.